If you or a loved one were to receive a diagnosis of a serious or life-threatening disease, you would likely want access to a U.S. Food and Drug Administration (FDA) approved safe and effective medicine as soon as possible. That’s precisely why the accelerated approval pathway was created back in 1992 at the urging of patient advocates. Since then, it has been a lifeline for millions of patients. Primarily utilized for cancers, rare diseases and HIV/AIDS, the pathway allows patients earlier access to potentially lifesaving medicines – often when no other treatment is available and when patients are facing difficult odds.
Here are three key things to know about this patient need-focused pathway and its impact over the last 30 years:
The accelerated approval pathway was developed by the FDA in 1992 as a response to the growing HIV/AIDS epidemic and calls by patient advocates for the agency to expedite access to promising medicines in development.
- Developing an innovative medicine is a lengthy and complex process that takes an average of 10 to 15 years. But patients fighting serious or life-threatening diseases – including hard-to-treat cancers – often don’t have time on their side. Amid the growing HIV/AIDS epidemic in the early 1990s and in response to the urging of patient advocates, the FDA designed the accelerated approval pathway to allow patients earlier access to potentially lifesaving treatments — an action that, no doubt, saved lives then and has been improving and extending lives for the last 30 years. For example, accelerated approval awarded to two therapies for non-small cell lung cancer allowed more than 500,000 patients to get those treatments sooner, allowing the combined patient population to live nearly 200,000 additional years compared with expected survival had the medicines not been available.
Medicines granted accelerated approval must adhere to the same standards for establishing safety and effectiveness as medicines receiving a traditional FDA approval.
- Medicines granted accelerated approval must provide substantial evidence of effectiveness per the FDA based on “adequate and well controlled clinical investigations.” The pathway specifically allows FDA to approve drugs based on a determination that the product has an effect on certain surrogate endpoints or intermediate clinical endpoints. Surrogate or intermediate endpoint can be based on a laboratory measurement (like blood glucose level for diabetes), radiographic image (like tumor size reduction), physical sign (like blood pressure for cardiovascular disease) or other measure. For instance, reduction of viral load in HIV patients, reduced tumor size in cancer patients or alleviation of symptoms can all be used to show a treatment’s benefit to patients. Congress has clarified, through statute, that the accelerated approval pathway does not alter the standards of evidence required for approval.
After a medicine is granted accelerated approval, companies are required to conduct, and provide updates on, confirmatory trials and the FDA is required to make this information publicly available.
- Companies are required to conduct confirmatory studies of medicines granted accelerated approval and are subject to reporting requirements on the status of these studies. The FDA is required to track, and make publicly available, progress of confirmatory trials.
- It is important to understand the challenges of conducting confirmatory trials. There are a number of reasons that a confirmatory trial may take longer than originally planned, including the inability to enroll patients as quickly as anticipated, for example due to patients enrolling in other studies aimed at the same population, patients being less willing to volunteer for studies of FDA-approved medicines or small patient populations.
The accelerated approval pathway has demonstrated considerable success for patients facing serious or life-threatening diseases and provided earlier access to treatments for illnesses with unmet medical needs. As policymakers examine the pathway, it is vital any changes do not hinder the significant benefits stemming from the program expediting patient access to lifesaving medicines.
To learn more about the importance of the accelerated approval pathway, click here.
Lucy Vereshchagina, PhD
Dr. Lucy Vereshchagina is executive vice president of science and regulatory advocacy at PhRMA. In this role, Dr. Vereshchagina leads PhRMA’s science and regulatory advocacy department supporting PhRMA’s policy, advocacy and science priorities, as well as global regulatory advocacy efforts, including the International Council for Harmonization (ICH). Dr. Vereshchagina was the lead PhRMA negotiator for both PDUFA VII and BsUFA III and testified before Congress on the agreements’ reauthorization.
Prior to joining PhRMA in 2012, Dr. Vereshchagina spent over 12 years with the FDA & Healthcare Practice at an international law firm and the Investigational Drug Branch at the National Cancer Institute. She has a master’s degree in Biochemistry and Chemistry, earned her Ph.D. in Chemistry at the Catholic University of America, and completed her post-doctoral studies in molecular biology and immunology at the Walter Reed Army Institute of Research.
Lucy Vereshchagina
https://www.linkedin.com/in/lucy-vereshchagina-phd-416b27a/
Executive Vice President of Science and Regulatory Advocacy
Mass compounding puts patients at risk
Advancing patient care: A look at new medicines approved in 2025
Knockoffs of FDA-approved drugs put patients at risk
PDUFA: Essential to America’s edge in drug development and patient access
Major drug compounder is spending millions on misleading Super Bowl ad
More oversight needed of unapproved medicines that threaten patients’ health
The use of real-world data in drug development
New analysis: Accelerated approval pathway is changing lives in underserved communities
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
Florida’s importation plan puts patients in danger
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
Decentralized clinical trials and the future of drug development
How FDA’s modernization strategy could improve drug development
Setting the record straight on accelerated approval
A guide to MedPAC’s Part B vote today
FDA should remain the authority on the safety and effectiveness of medicines
MedPAC proposal threatens access to medicines in Part B
Novel medicines approved in 2022 offer increased treatment options for patients
What you should know about real-world evidence and drug development
PDUFA and BsUFA reauthorizations are wins for patients
Word of the Month: Biomarkers and surrogate endpoints
Why drug importation is bad for Americans
Ensuring timely reauthorization of PDUFA and BsUFA
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
The importance of timely PDUFA and BsUFA reauthorization
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition
Meeting Tomorrow: Looking ahead to PDUFA VII
The impact of monoclonal antibodies and COVID-19 recovery
PDUFA VII is critical for future biopharmaceutical innovation and for patients
How strengthening the biosimilar marketplace benefits patients
The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Nearly 400 cell and gene therapies in development to target a broad range of diseases
PhRMA submits comments on FDA’s proposed rule on drug importation
Drug importation: An old idea that is still a bad idea
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
What they’re saying: Safety is top concern for recent drug importation proposal
ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals
PhRMA responds to Florida’s request for information on drug importation
Guest Post: Using the patient voice to go boldly
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
PhRMA CEO raises concerns with Florida importation proposal, highlights reforms needed to lower costs for patients
Guest post: Hearing from patients on Rare Disease Day
Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation
Look at the facts. Drug importation is dangerous.
Why state drug importation pilot programs don’t work
Putting 2018 medicine approvals in context
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
Balancing innovation and competition in the biologics marketplace
New analysis shows that more medicines worldwide are available to U.S. patients
Securely dispose of your unwanted medicines on National Take Back Day
Spending on medicines grew less than one percent in 2017
Rare Disease Day: Unmet need inspires innovation
Innovation comes in many forms, including new and expanded uses of existing medicines
ICYMI: Why 2017 medicine approvals matter
New surveys find payers and providers want more data from biopharmaceutical companies
Supporting opportunities for enhanced competition in the marketplace
The Washington Post retracts PhRMA claim in opioid story
PhRMA response to Washington Post and 60 Minutes stories
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Protect your health: Important disaster preparedness tips for Harvey and Irma
PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis
Opportunities to build upon enhanced competition for medicines in the marketplace
Why reauthorization of PDUFA matters
A critical opportunity to prevent prescription drug abuse
Former law enforcement officials raise concerns with drug importation proposals
Resources for understanding the dangers of drug importation
Guest Post: The importance of a modern FDA in drug discovery
How drug importation schemes could increase U.S. law enforcement burdens
Case Study: How one online pharmacy knowingly endangered U.S. consumers
Why drug importation threatens patient safety
Fact Check Friday: The truth about drug importation and patient safety
What you don’t know about importation from Canada
Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
Three things to know about the accelerated approval pathway
FDA
Prescription Drug Safety
Accelerated Approval
Three things to know about the accelerated approval pathway
Three things to know about the accelerated approval pathway